To find the proportion of ESI enrollees with a prescription for GLP-1 drugs, outpatient pharmaceutical claims from 2012 to 2022 in the Merative MarketScan Commercial Database were used
Key Products: Aleniglipron (GSBR-1290), a once-daily oral, nonpeptide small molecule GLP-1 receptor agonist
antitumor effects persisted despite partial weight regain and were associated with durable systemic and tumor immune reprogramming
Weight loss results In a 2022 review of 22 studies that included more than 17,000 people with or without type 2 diabetes treated with semaglutide or liraglutide: More than 50% of participants treated with either semaglutide or liraglutide lost 5% or more of their starting weight after an average of 39 weeks on the medicine About 17% of participants lost 10% or more of their body weight in the same period A phase 3 clinical trial studied treatment with tirzepatide in people with obesity and found that it produced substantial and sustained weight loss at various dose strengths
Other factors, such as diet and exercise, will affect weight loss success
Since retatrutide is a subcutaneous injection (not an oral drug), food timing is irrelevant